In this study, we used the Luminex assay, as it has the ability to measure simultaneously SARS-CoV-2 anti-nucleocapsid (anti-N), anti-RBD, and anti-spike (anti-S) antibodies to identify participants with previous infection and to evaluate vaccine response. This evidence concerns the gene CHMP5 and infection.